Skip to main content
SpringerLink
Log in

The Role of Naltrexone in the Management of Drug Abuse

  • Leading Article
  • Published:
Medical Toxicology and Adverse Drug Experience Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Atkinson RL, Williams FL, Drake CR, Berke LK, Bibbs ML. Naltrexone for weight loss in obesity. Paper presented at the 4th International Congress on Obesity, 1983

  • Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, et al. Effects on long-term therapy with naltrexone on body weight in obesity. Clinical Pharmacological Therapy 38: 419–422, 1985

    Article  CAS  Google Scholar 

  • Blumberg H, Dayton HB. Naloxone and related compounds. In Kosterlitz et al. (Eds) Agonist and antagonist actions of narcotic analgesic drugs, pp. 110–119, Macmillan, New York, 1973

    Google Scholar 

  • Blumberg H, Dayton HB, Wolf PS. Analgesic properties of the narcotic antagonist EN-2234 A. Pharmacologist 10: 201, 1968

    Google Scholar 

  • Blumberg H, Pachter IJ, Matossian Z. US Patient 3,332,950, 25 July, 1967

  • Brahen LM, Henderson RK, Capone T, Kordal N. Naltrexone treatment in a jail work-release program. Journal of Clinical Psychiatry 49(2): 42–45, 1984

    Google Scholar 

  • Brahen LM, Weichert V, Capone T. Narcotic antagonist treatment of the criminal justice patient: institutional vs. outpatient. In Julius et al. (Eds) Narcotic antagonists: naltrexone progress report, National Institute on Drug Abuse Research Monograph Vol. 9, pp. 93–98, US Government Printing Office, Washington DC, 1976

    Google Scholar 

  • Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond Jr DR. The clinical use of clonidine in abrupt withdrawal from methadone. Archives of General Psychiatry 38: 1273–1277, 1981

    Article  PubMed  CAS  Google Scholar 

  • Crowley TJ, Wagner JE, Zerbe G, MacDonald M. Naltrexone-induced dysphoria in former opioid addicts. American Journal of Psychiatry 142: 1081–1084, 1985

    PubMed  CAS  Google Scholar 

  • Freedman A, Fink M, Sharoff R, Zaks A. Clinical studies of cyclazocine in the treatment of narcotic addiction. American Journal of Psychiatry 124: 1499–1504, 1968

    PubMed  CAS  Google Scholar 

  • Ginzburg HM. Use of clonidine or lofexidine to detoxify from methadone maintenance or other opioid dependencies. In Cooper et al. (Eds) Research on the treatment of narcotic addiction: state of the art, pp. 174–211, NIDA Treatment Research Monograph Series, Rockville, Maryland, 1983

  • Ginzburg HM. Substance substitution: do methadone maintenance patients become alcoholics? In Seixas (Ed.) Currents in alcoholism, Vol. 2, pp. 253–268, Grune & Stratton, New York, 1977

    Google Scholar 

  • Ginzburg HM. Acquired immunodeficiency syndrome (AIDS) among intravenous drug users. Public Health Reports 99: 206–211, 1984a

    PubMed  CAS  Google Scholar 

  • Ginzburg HM. Naltrexone: its clinical utility. NIDA Treatment Research Report, Rockville, Maryland, 1984b

  • Ginzburg HM. Naltrexone: its clinical utility. Advances in Alcohol and Substance Abuse 5: 83–103, 1986

    Article  Google Scholar 

  • Ginzburg HM, Glass WJ. The role of the National Institute on Drug Abuse in the development of naltrexone. Journal of Clinical Psychiatry 49(2): 4–6, 1984

    Google Scholar 

  • Gold MS, Pottash AC. The neurobiological implications of clonidine HCl. Annals of the New York Academy of Sciences 362: 191–202, 1981

    Article  PubMed  CAS  Google Scholar 

  • Gold MS, Redmond DE, Kleber HD. Clonidine in opiate withdrawal. Lancet 1: 929–930, 1978

    Article  PubMed  CAS  Google Scholar 

  • Gold MS, Dackis CA, Washton AM. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in Alcohol and Substance Abuse 3: 19–39, 1984

    Article  PubMed  CAS  Google Scholar 

  • Greenstein RA, Arndt IC, McLellan AT, O’Brien CP, Evans B. Naltrexone: a clinical perspective. Journal of Clinical Psychiatry 49(2): 25–28, 1984

    Google Scholar 

  • Gritz ER, Shiffman SM, Jarvik ME, Schlesinger J, Charuvastra VC. Naltrexone: physiological and psychological effects of single doses. Clinical Pharmacology and Therapeutics 19: 773–776, 1976

    PubMed  CAS  Google Scholar 

  • Herman BH, Holtzman SG. Repeated administration of naltrexone and diphenorphine decreases food intake and body weight in squirrel monkeys. Life Sciences 34: 1–12, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hollister LE, Johnson K, Boukhabza D, Gillespie HK. Aversive effects of naltrexone in subjects not dependent on opiates. Journal of Drug and Alcohol Dependence 8: 37–41, 1981

    Article  CAS  Google Scholar 

  • Hyman BT, Eslinger PJ, Damasio AR. Effect of naltrexone on senile dementia of the Alzheimer type. Journal of Neurology, Neurosurgery, and Psychiatry 48: 1169–1171, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ionescu F, Klee W, Katz R. Antagonist potency and receptor binding. Life Sciences 16: 1973–1974, 1975

    Article  Google Scholar 

  • Jaffe JH. Drug addiction and drug abuse. In Gilman AG et al. (Eds) The pharmacological basis of therapeutics, 6th ed., pp. 535–584, Macmillan, New York, 1980

    Google Scholar 

  • Jaffe JH, Brill L. Cyclazocine, a long-acting narcotic antagonist: its voluntary acceptance as a treatment modality by narcotic abusers. International Journal of the Addictions 1: 99–123, 1966

    Google Scholar 

  • Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Archives of General Psychiatry 42: 1063–1066, 1985

    Article  PubMed  CAS  Google Scholar 

  • Judson BA, Goldstein A. Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers. Journal of Drug and Alcohol Dependence 10: 269–282, 1982

    Article  CAS  Google Scholar 

  • Judson BA, Goldstein A, Inturrisi CE. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Journal of Drug and Alcohol Dependence 7: 325–346, 1981

    Article  CAS  Google Scholar 

  • Judson BA, Himmelberger DU, Goldstein A. The naloxone test for opiate dependence. Clinical Pharmacology and Therapeutics 27: 492–501, 1980

    Article  PubMed  CAS  Google Scholar 

  • Kleber HD. Naltrexone. Journal of Substance Abuse Treatment 2: 117–120, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kleber HD, Kosten TR, Gaspari J, Topazian R. Nontolerance to the opioid antagonism of naltrexone. Biological Psychiatry 20: 66–72, 1985

    Article  PubMed  CAS  Google Scholar 

  • Licko V. Overview of human pharmacokinetics of naltrexone. In Willette et al. (Eds) Naltrexone antagonists: naltrexone pharmacochemistry and sustained-release preparations, National Institute on Drug Abuse Research Monograph, Vol. 28, pp. 161–171, US Government Printing Office, Washington DC, 1981

    Google Scholar 

  • Ling W, Wesson DR. Naltrexone treatment for addicted healthcare professionals: a collaborative private practice experience. Journal of Clinical Psychiatry 49(2): 46–48, 1984

    Google Scholar 

  • Lowy MT, Yim GKW. The effect of naltrexone is independent of its suppressant effect on water intake. Neuropharmacology 20: 883–886, 1981

    Article  PubMed  CAS  Google Scholar 

  • MacDonald MG, Moss IR, Kefale GG, Ginzburg HM, Fink RJ, et al. The effect of naltrexone on apnea of prematurity and on plasma b-endorphin-like immunoreactivity. Developmental Pharmacology and Therapeutic 9: 301–309, 1986

    CAS  Google Scholar 

  • McNicholas LF, Martin WR. New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs 27: 81–93, 1984

    Article  PubMed  CAS  Google Scholar 

  • Maggio CA, Presta E, Bracco EF, Vasselli JR, Kissileff HR, et al. Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Research Bulletin 14: 657–661, 1985

    Article  PubMed  CAS  Google Scholar 

  • Mandenoff AF, Fumeron F, Apfelbaum M, Margules DL. Endogenous opiates and energy balance. Science 215: 1536–1538, 1982

    Article  PubMed  CAS  Google Scholar 

  • Martin WR, Gorodetzky CW. Demonstration of tolerance to and dependence on N-allylnormorphine (nalorphine). Journal of Pharmacology and Experimental Therapeutics 150: 437–442, 1965

    PubMed  CAS  Google Scholar 

  • Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Archives of General Psychiatry 28: 784–791, 1973

    Article  PubMed  CAS  Google Scholar 

  • Meyer MC, Straughn AB, Man-Wail P, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. Journal of Clinical Psychiatry 49(2): 15–19, 1984

    Google Scholar 

  • Mitchell JE, Morley JE, Hatsukami D. A double-blind, placebo-controlled trial of naltrexone in obese males. Paper presented at the Neural and Metabolic Bases of Feeding, Satellite Symposium of the Neuroscience Society Meeting, 1984

  • National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate dependent individuals. Archives of General Psychiatry 35: 335–340, 1978

    Article  Google Scholar 

  • Petursson H, Lader MH. Benzodiazepine dependence. British Journal of Addiction 76: 133–145, 1981

    Article  PubMed  CAS  Google Scholar 

  • Rosenkrantz H. Physiologic and morphologic changes in mice and rats fed naltrexone HCl for 24 months. Journal of Clinical Psychiatry 49(2): 11–14 1984

    Google Scholar 

  • Senay EC, Dorus W, Goldberg F. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Archives of General Psychiatry 34: 361–367, 1977

    Article  PubMed  CAS  Google Scholar 

  • Szara SI, Ludford JP (Eds). Benzodiazepines: a review of research results, 1980, National Institute of Drug Abuse Research, Monograph 33, US Government Printing Office, Washington DC, 1982

    Google Scholar 

  • Tennant FS, Rawson RA, Cohen AJ, Mann A. Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry 49(2): 42–45, 1984

    Google Scholar 

  • Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. In Willette et al. (Eds) Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations, National Institute on Drug Abuse Research Monograph 28, pp. 147–158, US Government Printing Office, Washington DC, 1981

    Google Scholar 

  • Verebey K, Volavka J, Mule SJ. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacology and Therapeutics 20: 315–328, 1976

    PubMed  CAS  Google Scholar 

  • Volavka J, Resnick RB. Treatment of accidental naltrexone-induced withdrawal. Correspondence. American Journal of Psychiatry 133: 233, 1976

    CAS  Google Scholar 

  • Washton AM, Resnick RB. Clonidine for outpatient detoxification: outpatient clinical trials. American Journal of Psychiatry 137: 1121–1122, 1980

    PubMed  CAS  Google Scholar 

  • Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry 49(2): 39–41, 1984

    Google Scholar 

  • Willette RE, Barnett G (Eds). Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations, National Institute on Drug Abuse Research Monograph 28, US Government Printing Office, Washington DC, 1981

    Google Scholar 

  • Wikler A. Recent progress in research on the neurophysiologic basis of morphine addiction. American Journal of Psychiatry 105: 329–338, 1948

    PubMed  CAS  Google Scholar 

  • Zaks A, Jones T, Fink M, Freedman AM. Naloxone treatment of opiate dependence. Journal of the American Medical Association 215: 2108–2110, 1971

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiology Branch, AIDS Program, National Institute of Allergy and Infectious Diseases, Room 753, Westwood Building, 9000 Rockville Pike, Bethesda, Maryland, 20892, USA

    Harold M. Ginzburg (Chief) & Mhairi G. MacDonald

  2. George Washington School of Medicine and Health Sciences, Children’s Hospital National Medical Center, Washington DC, USA

    Harold M. Ginzburg (Chief) & Mhairi G. MacDonald

Authors
  1. Harold M. Ginzburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mhairi G. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The opinions expressed in this article are those of the authors and not necessarily those of the National Institute of Allergy and Infectious Diseases.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ginzburg, H.M., MacDonald, M.G. The Role of Naltrexone in the Management of Drug Abuse. Drugs 2, 83–92 (1987). https://doi.org/10.1007/BF03260007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03260007

Keywords

Search

Navigation